DAT SPECT and Procedural Motor Skills in Parkinson's Disease

NCT ID: NCT03076307

Last Updated: 2017-07-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

9 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-10-18

Study Completion Date

2017-07-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients with Parkinson's disease (PD) are known to be affected by subtle cognitive impairment early in the disease course, mostly in the executive field. Procedural motor skills, mainly controlled by the basal ganglia associative loop (in particular dorsal caudate nucleus) (Rodriguez-Oroz et al., 2009), have also been studied in patients with PD (Schnider et al., 1995; Muslimovic et al., 2007; Terpening et al., 2013). However, the correlation of dopaminergic 123I-FP-CIT SPECT imaging and cognitive impairment has not been assessed. One reason is the absence of reference values for striatal uptake until recently. Last year, the investigators established local uptake reference values for DAT imaging based on a large cohort of subjects with non-degenerative conditions (Nicastro et al., 2016) and can therefore use these values to precisely assess uptake loss in patients with PD.

With the present study, the investigators expect to enroll patients with early PD for whom a 123I-FP-CIT SPECT has been previously performed in the center. Subjects will perform a specific motor task based on mirror-drawing of star-shaped figures. This will be done by inverting the direction of horizontal/vertical computer mouse movements on the screen. Speed and error rates will be assessed for patients as well as healthy control subjects. Correlation with striatal SPECT uptake, especially caudate nucleus uptake, will be analyzed for PD patients. In addition, resting-state EEG will be performed for all subjects. General medication and dopaminergic drugs in particular, whenever used, will not be discontinued. For all subjects enrolled in the study, cognitive and neurological examination will be performed.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Parkinson's disease

Group Type EXPERIMENTAL

Procedural Motor Skills with mirror-drawing of figures

Intervention Type BEHAVIORAL

Evaluation of error rate and speed for completion of a procedural motor task

Control group

Group Type ACTIVE_COMPARATOR

Procedural Motor Skills with mirror-drawing of figures

Intervention Type BEHAVIORAL

Evaluation of error rate and speed for completion of a procedural motor task

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Procedural Motor Skills with mirror-drawing of figures

Evaluation of error rate and speed for completion of a procedural motor task

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \> 18 year-old
* Diagnosis of PD with onset \<2 years from enrollment
* Available DAT SPECT performed in Geneva University Hospitals \<6 months before inclusion


Age- and sex-matched control patients

* Age \> 18 year-old
* No known neurological condition interfering with motor and cognitive abilities
* No medication interfering with central nervous system (including antidepressants, antipsychotics, hypnotics)

Exclusion Criteria

* Major depressive state (Hospital Anxiety and Depression scale ≥11 for depression score)
* Cognitive decline (Mini-Mental Score ≤ 22/30)
* Debilitating tremor (Movement Disorders Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III - rest, postural and action tremor ≥2/4)
* Significant akinesia (MDS-UPDRS III hand brady-akinesia score ≥2/4)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Geneva

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Nicolas Nicastro

Dr. Med. Nicolas NICASTRO

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Division of Neurorehabilitation, Geneva University Hospitals

Geneva, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CCER 2016-01469

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.